home > news > detailed info

Industry-First Cancer Screening Technology Boosted by Biomedical Grant Funding

Medicines Discovery Catapult

Medicines Discovery Catapult and SMi secure funding to validate cancer biomarker technology

Medicines Discovery Catapult (MDC) and SMi have secured a Biomedical Catalyst (BMC) grant to validate a new approach to detect cancer biomarkers. It will transform their use for routine cancer screening and enable monitoring of treatment efficacy in real time.

Liquid biopsies are where a simple blood sample is analysed for tiny quantities of cancer-related material (cancer biomarkers). They are increasingly used for early cancer detection, improved treatment guidance (as a companion diagnostic), and to check for recurrence. However, many factors in current approaches hinder their routine use. These include the complexity of test procedures, the expertise and time needed to run tests, and the high costs. New solutions are needed to speed up the adoption of the promising technique to diagnose this devastating disease.

Under the BMC-funded project, MDC will use SMi's super-resolution optical platform to demonstrate a new approach that inspects liquid biopsies at single molecule resolution. This will allow researchers to detect and quantify each cancer indicator. As SMiís optical platform can be adapted for an almost unlimited range of molecule types, it can be widely used across research and diagnosis applications. This was shown most recently in another successful MDC and SMi project to detect viral genomes, viral proteins, and the associated antibodies the patient produces in response to viral infection.

A crucial part of the current BMC-funded cancer project is screening paired samples using SMiís optical platform and Ďgold-standardí droplet digital PCR (ddPCR) testing. These technologies are available in MDC's cutting-edge laboratories at Alderley Park in Cheshire.

SMiís technology will overcome current technical challenges by rapidly and simultaneously detecting different cancer-associated biomarkers, from a single patient blood sample, in less than one second. This capability will be game-changing at a time when the number of cancer biomarker panels is growing, but the market still relies upon complex biochemical assays and costly, time-consuming next-generation sequencing (NGS) techniques.

Dr Matthew Burnham, Lead Scientist at Medicines Discovery Catapult, said: "MDC is delighted to continue our partnership with SMi, to transform screening and treatment for cancer patients. We have supported the evolution of SMiís unique and innovative technology for more than a year. We are pleased to have secured this funding to build upon our first joint study on infectious disease detection.

ďMDC has access to the current gold-standard diagnostic devices and is uniquely placed to help SMi compare these results with its platformís results. Our in-house expertise will help SMi validate the cancer biomarker approach. This will contribute to quicker, more accurate diagnoses for this devastating disease affecting so many people."

Dr Andrew Thompson, CEO at SMi, said: ďSMi is creating a unified platform that is based upon single molecule imaging. It provides unprecedented performance in an automated, user-friendly format and will have far-reaching benefits for diagnosis and the discovery of new medicines. This latest funding allows us to demonstrate our ability to rapidly screen for multiple biomarkers and multiple cancer types, allowing us to accelerate our product development and deliver accurate diagnosis to patients much sooner. MDCís scientists have a broad range of talents and in-house resources, and we are looking forward to continue growing our close partnership."

SMi's technology combines an automated super-resolution instrument, consumable sensor chips and software analysis. It uses SMi's proprietary expertise in complex image analysis and particle detection. It is unique in many ways, not least as there is currently no other diagnostic technology that can achieve the molecular detection of DNA and protein biomarkers needed to improve cancer diagnosis.

MDC reshapes drug discovery for patient benefit and transforms great UK science into better treatments through partnership. It works to tackle industry-led challenges and overcome the barriers that limit today's drug discovery with effective interventions.

For more information, please visit:
phone 01625 238734
email Medicines Discovery Catapult, Block 35, Mereside Alderley Park, Macclesfield, Cheshire, SK10 4ZF
Print this page
Send to a friend
News and Press Releases

Nemera and Nelson Labs Europe strengthen partnership to offer integrated services to customers

This strategic alliance will give a unique advantage to pharmaceutical & bio-tech customers - accelerating the go-to-market of their drug-device combination products by offering analytical chemistry, drug compatibility lab testing and expert advice.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B


Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

Industry Events

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023)

12-13 June 2023, Hilton Geneva Hotel & Conference Centre, Geneva, Switzerland

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023) gathers top-level management from pharmaceutical companies of manufacturing, primary and secondary packaging, purchasing, and supply chain and procurement sectors, CMOs and CDMOs leaders, heads from government and institution on 12-13, June, 2023 in Geneva, Switzerland.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement